-
-
I bought my gun already if there's 0% growth Bro.
Nah man...calm down...let's just enjoy we don't know for now. I have high hopes though since the CEO said "totally expect to beat propecia" n they had 10 years to put that stuff on someone's scalp...come on it's safe treatment I'd take 40 litters of replicels sauce on my scalp any day.
We still have ARI though, but I don't think that would make us look like rockstars....still better than SHINY BALD HEAD I hate that *!#@.Comment
-
We know it provides results. So what do you mean "work"?
If we're all out there saying I'll pay $50K and they see it you're providing them info that we'd all pay $50K.
Engage PR brains people! Lets plant the $10K story now and incept them. Say after me "we'd only ever pay $10K for Histogen or Replicel" :PComment
-
Actually it would be in there best interest to provide a service at a reasonable price, if they inflate the price they will only be able to gauge a small portion of society however if they keep the costs as low as possible they will see a much great return as it will encourage a larger group of people to undergo the procedure.
One thing I have not seen mentioned here is this, lets just say hypothetically that Histogen, Relicel and Aderans release their finds, procedure and product to the market all at the same time or in succession whilst the choice would be great as they all seem to have a different approach to one another it can may become an issue, for example no one really knows if you are locking yourself out from another competitors procedure if you are already under the care of another, they may not mix.
Let just say you jumped on board Replicel and it did not live up to its claims or you were unhappy with the results...
Its a costly business I'm sure and we are only at the tip of the iceberg really.Comment
-
This is a very interesting point, and one I had not considered previously. I would hope, as I'm sure others would as well, that this would not be the case. In any case, I would think a person's propensity regarding choice of which company to use is largely, if not totally, dependent on their respective release dates.Comment
-
I'd say that we probably already know that they will do better than 0% growth. Aderans, who is using a very similar cell based approach, have demonstrated growth in humans. Granted, it wasn't the best and they're now trying to tune up their method. But, none the less, it was growth. Replicel, has a very strong scientific team and a decade of prework behind them, that gives me more confidence in them than Aderans, so i'm hoping they can do substantially better.
Plus, Aderans is significantly further along in the process than replicel, so, they will mostly likely be first to market. It would behoove replicel to get better results than Aderans. If they don't, and Aderans makes it to market first, not only will they not be able to take market share from them, but, they will probably have a more difficult time with the FDA. I believe with medications, new drugs have to provide either better efficacy or better safety profiles than existing FDA approved treatments, or else there is a tendency for them to be rejected. My guess is Replicel is very aware of this. That they're proceeding forward, speaks to their optimism.
My hope is that Aderans does well and shows "good" results from their multi armed trial. And then i hope that Replicel absolutely trounces them.Comment
-
I wouldn't read to much into Replicel's much discussed "confidence." Being a publicly traded company trading @ $2/share on an over the counter exchange, it is the the CEO's job to be cheerleader and chief and maximize shareholder value by creating as much optimism as possible to increase the share price and to convince suckers (like myself) to buy stock. All without being deliberately misleading of course (notice their language is chosen very carefully).Comment
-
Even if it's something "just" better than Propecia, and topical/injectable, that would be a big breakthrough, let's be honest... Just think how long Propecia has been on the market without a seriously better (and safer!) treatment overtaking it.
I agree with Hair Bear's point about pricing.
Additionally, I sure hope that as many of these next-gen treatments enter the market as possible, as market competition = (eventually) lower prices.Comment
-
Yeah I hope it not be the case also however here in lies the problem, a persons choice may be heavily influenced by the release dates and as such it may not be the best decision as someone has mentioned that any other company seeking FDA approval will have to be better than the currently approved option therefore my concerns can and will become relevant it may even hold back the approval as the new company (solution B) may have to prove that it can be used after solution A which has already been approved much to the same way many companies such as histogen have tested that their methods work with human trialist under the influence of minoxodil and or propecia.Comment
-
I'm actually quite excited about HSC. I know more people put they're faith into Replicel and it will (if successfull!!) be the better treatment.
But my understanding is that HSC is the closest to being released and it doesn't require a few months waiting for hair cells to multiply. Therefore you could go in, have a few injections and watch your hair regrow over a year or more, Histogens site says by 75%! Granted this hair would be still susceptible to DHT but if it lasts for 5 years, maybe more on propecia/dut, then if the price was reasonable then I would have no complaints going to have an injection every 5 or more years......
just my thoughtsComment
-
They are OTC because they are not incorporated in the USA.
If they choose to officially list in the on the NASDAQ or NYSE they have to do a couple things. Namely they must file regularly reports with the SEC. As an OTC they don't have to.
Second, they must incorporate in the USA or incorporate on their native exchange (the TSX) and create whats called an ADR class of share.Comment
-
Not Correct. They are traded on the newly formed (2010) OTCQB which is the middle tier of the OTC market that does in fact report to the SEC or a U.S. banking regulator.
Comment
Tweet
Comment